Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT02770521
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
Biomarker Study in Participants With Migraine
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT02766517
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States
🇺🇸Parexel Early Phase Unit at Glendale, Glendale, California, United States
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT02763566
- Locations
- 🇧🇷
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇳Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
🇨🇳Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
- Conditions
- HealthyType 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02759107
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇺🇸Miami Research Associates, South Miami, Florida, United States
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT02760602
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Center for Neurosciences, Tucson, Arizona, United States
🇺🇸Arizona Health Sciences Center, Tucson, Arizona, United States
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 303
- Registration Number
- NCT02757352
- Locations
- 🇺🇸
Institute of Arthritis Research, Idaho Falls, Idaho, United States
🇺🇸TriWest Research Assocaites, El Cajon, California, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
A Study of Baricitinib (LY3009104) in Healthy Chinese Participants
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT02758613
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Beijing, China
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Saline Solution - IVDrug: LY3303560 - IVDrug: LY3303560 - SC
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT02754830
- Locations
- 🇺🇸
PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸Parexel Early Phase Unit at Glendale, Glendale, California, United States
Study of Galunisertib in Healthy Participants
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT02752919
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY900014
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02752087
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore